GENinCode – interims, with “revenues have not been as strong as hoped” how’s the balance sheet position now?
‘Predictive genetics’ company GENinCode (GENI) has announced results for the first half of the 2026 calendar year including “successful completion of £4.3m net placing in Feb 2026 to support scale up and commercialisation… adjusted EBITDA losses have reduced over the period and are expected to improve further in the second half as revenues improve”. So what about a current 0.70p share price, 20% lower?

